Ajanta Pharma Limited

Ajanta Pharma Limited, announces the final approval from US FDA* and launch of Omeprazole and Sodium Bicarbonate Capsules in the US market

Ajanta Pharma Limited, announces today the launch of Memantine Hydrochloride Tablets in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc.

Ajanta Pharma Limited, today announced the receipt of final approval for Voriconazole Tablets (50mg & 200mg), from the U.S. Food and Drug Administration (FDA).

Q4 FY 2016 performance highlights (Consolidated) • Revenue from operations grew 14% at Rs. 426 cr. against Rs. 372 cr. • EBITDA growth of 6% at Rs. 141 cr. against Rs. 133 cr., EBITDA at 33% of revenue.

Operating Revenue up 16%, PAT up 20% for Q3 FY2016 (Consolidated – 3rd Quarter and 9 Months Results, FY 2015-16)

Ajanta Pharma USA Inc., a subsidiary of Ajanta Pharma Limited, announced today the launch of Montelukast Sodium IR Tablets (10mg) and Montelukast Sodium Chewable Tablets (4mg & 5mg).

Mumbai, 16th November 2015: Ajanta Pharma USA Inc., a subsidiary of Ajanta Pharma Limited, announced today the launch of Montelukast Sodium Oral Granules (4mg), a bioequivalent generic version of SINGULAIR® Granules, in the US market.

Mumbai, 30th October 2015: Ajanta Pharma Limited, a specialty focused pharmaceutical formulation company reported today its performance for the 2nd quarter and Half year ended 30th September 2015.

Fortune India has published list of 500 mid-size companies and ranked them on various parameters based on the results of 2013-14. Ajanta Pharma features very prominently in the lists.

Key financial & performance highlights – Consolidated • Revenue from operations grew 22% at Rs. 391 cr. • EBITDA growth of 26% at Rs. 123 cr. • Profit before tax grew 35% at Rs. 118 cr. • Profit after tax grew 41% at Rs. 84 cr.